US SEC Trading Suspension Halt Orders — July 23, 2026

**Nuvve Holding Corp.:** Received final delisting determination with trading suspended July 24, 2026; stock will move to OTC Pink. No insider buying reported, signaling a high probability of value destruction post-suspension.

**Aprea Therapeutics:** Granted a second 180-day grace period until January 19, 2027, to regain minimum bid price compliance. No insider activity or capital allocation actions reported, leaving a binary catalyst.

**Fly-E Group:** Filed delinquent 10-K on July 23, 2026, immediately after receiving Nasdaq delinquency notice, effectively curing the deficiency. This rapid resolution reduces delisting risk, but no insider buying or capital actions suggest limited confidence.

**InspireMD:** Non-compliance with bid price rule since June 3 through July 16, 2026; 180-day compliance period ends January 13, 2027. No reverse stock split announced yet but hinted, creating uncertainty. No insider transactions reported.

**Shore Bancshares:** Governance violation from $10,555 in legal payments to a director's firm; director resigned from Audit Committee the day before disclosure. The small dollar amount suggests a procedural lapse, not a structural governance failure.

**All Five Companies:** Zero insider trading activity (no buys or sells) reported across all filings during this period, indicating management is not signaling conviction through personal investment at these depressed levels.

**Nuvve Holding Corp.:** Triple violation (bid price, equity, and periodic reporting) led to the only immediate delisting action. Stock expected to trade on OTC Pink, drastically reducing liquidity and analyst coverage.

**Fly-E Group vs. Nuvve:** Both had periodic reporting failures, but Fly-E cured within 2 days while Nuvve did not. This contrast highlights operational capability differences in addressing compliance issues. [BULLISH for Fly-E, BEARISH for Nuvve]

**Nuvve Holding Corp.:** Immediate suspension on July 24, 2026. Stock will trade on OTC Pink with likely severe price dislocation and loss of institutional eligibility. No insider buying reported to offset downside.

**Aprea Therapeutics:** If bid price does not close at $1.00+ for 10 consecutive business days by January 19, 2027, delisting proceedings commence. The company has already used its first extension, raising the risk of failure.

**InspireMD:** Non-compliance since June 3, 2026. Without a reverse stock split or catalyst, share price could continue to drift below $1.00, increasing the likelihood of delisting after January 13, 2027.

**Shore Bancshares:** Governance non-compliance with Nasdaq Rule 5605(c)(2). While remediated, future inadvertent payments to director-affiliated firms could trigger renewed scrutiny.

**Nuvve Holding Corp.:** Also fails the Equity Rule (stockholders' equity below $2.5M). Even if reporting compliance were cured, quantitative listing standards remain unmet, making a return to Nasdaq challenging.

**Fly-E Group:** If the late-filed 10-K is not accepted, must submit a compliance plan by September 21, 2026. Failure to do so would re-escalate delisting risk.

**All Cash-Strapped Companies:** None of the five companies reported dividends, buybacks, or capital returns. Limited cash positions likely prevent them from supporting share prices through buybacks, increasing reliance on operational fixes or reverse splits.

**Sector Concentration:** All five are micro-cap (<$100M market cap) or nano-cap companies. Their thin liquidity and low share prices make them prone to volatility and potentially ineligible for many institutional portfolios.

**Fly-E Group/Catalyst:** Filed 10-K within 2 days of delinquency notice, and avoided compliance plan requirement. If share price stabilizes, the stock could rerate as delisting risk dissipates.

**Shore Bancshares/Governance Remediation:** Quick director resignation and committee restructuring removes the violation. As the only company with a clear and inexpensive fix, this could be a low-risk entry for governance-conscious investors.

**Aprea Therapeutics/Grace Period:** Has until January 19, 2027, to achieve 10 consecutive days above $1.00. If a positive catalyst (e.g., trial data) emerges, the stock could regain compliance without a dilutive reverse split.

**InspireMD/Potential Reverse Split:** If reverse split is executed, stock could immediately regain compliance. Similar companies have seen pre-split speculation. However, splits are often dilutive and signal financial stress.

**Nuvve Holding Corp./Appeal Path:** Company considering appeal to Nasdaq Listing and Hearing Review Council. If successful, trading could resume on OTC or Nasdaq, providing a mean-reversion trade. Extremely high risk.

**All Companies/No Insider Selling:** The absence of insider selling during these events could suggest management believes current prices are more likely to appreciate than further decline, though it could also reflect restricted trading windows.

**Timeline for Catalyst Calendar:** Key dates: Sep 21, 2026 (Fly-E compliance plan deadline), Jan 13, 2027 (InspireMD deadline), Jan 19, 2027 (Aprea deadline), Jul 24, 2026 (Nuvve suspension). These create defined events for event-driven strategies.

**Bid Price Rule Dominates Delisting Risk:** 3 of 5 filings (Nuvve, Aprea, InspireMD) involve failure to maintain $1.00 minimum bid price. This is the most common cause of non-compliance for micro-cap companies, often exacerbated by sector downturns or low trading volumes.

**Periodic Reporting Failures Concentrated:** 2 of 5 companies (Nuvve, Fly-E) failed to timely file quarterly/annual reports. The differing outcomes (Nuvve delisted, Fly-E cured) show that operational response time is critical to preserving listing status.

**Zero Insider Trading During Crisis Interval:** None of the 5 filings reported any insider transactions (buys or sells). In a typical sample, at least 1-2 insiders would trade. This could indicate restricted trading windows, but also suggests management is not confident enough to deploy personal capital.

**Capital Allocation Absent Across the Board:** No dividends, buybacks, or share repurchases were reported. All companies are conserving cash, which limits their ability to support stock prices organically and amplifies reliance on operational turnarounds or external catalysts.

**Governance Violations Emerge as a Watch Item:** Shore Bancshares’ inadvertent payment to a director's firm highlights the risk of small procedural errors triggering Nasdaq rules. Even small-dollar amounts ($10,555) can create material disclosure obligations.

**Micro-Cap Vulnerability to Delisting Cascades:** Nuvve’s triple violation (bid price, equity, reporting) shows how one failure (10-Q filing) can expose other quantitative weaknesses. Companies with multiple listing deficiencies face significantly shorter timelines to suspension.

**Nuvve Holding Corp. (NVVE):** Trading suspended July 24, 2026. Watch for OTC Pink quote update and any appeal filing. If appeal is granted, stock could relist.

**Fly-E Group (FLYE):** Filed delinquent 10-K on July 23. Watch for Nasdaq acceptance and any need for a compliance plan by September 21, 2026.

**Aprea Therapeutics (APRE):** Grace period ends January 19, 2027. Monitor share price for sustained rallies above $1.00 that could signal early compliance.

**InspireMD (NSPR):** 180-day compliance period ends January 13, 2027. Watch for any announcement of reverse stock split or alternative remedy.

**Shore Bancshares (SHBI):** Governance violation resolved. Monitor for any subsequent regulatory letters or Nasdaq-imposed conditions during the next quarterly filing.

**All Companies:** Watch for insider trading filings post-disclosure. If insiders begin buying after these disclosures, it could signal a bottom. If they sell, it would confirm risk.

**Nasdaq Listing Standards:** Monitor for any changes in Nasdaq's enforcement of bid price or reporting rules, as increased scrutiny could trigger more suspensions among micro-caps.